---
title: "Foyou Pharma: 6 products are expected to be selected for the 11th batch of national centralized drug procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263264213.md"
description: "Foyou Pharma announced that six of its products are expected to be selected in the 11th batch of national centralized drug procurement, including Fumaric Acid Lurasidone Tablets, Pravastatin Sodium Tablets, Cilostazol Tablets, Alendronate Sodium Tablets, Agomelatine Tablets, and Dopamine Hydrazine Tablets. If these products are selected and sales contracts are signed, it will help increase market share and have a positive impact on the company's future operating performance. At the same time, the products that the company did not win bids for, such as Dapagliflozin Tablets, did not generate sales in 2024, and the sales amount from January to September 2025 was CNY 2.9413 million, accounting for 0.1167% of the company's operating income during the same period, which will not have a significant impact on the company's production and operations"
datetime: "2025-10-29T10:37:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263264213.md)
  - [en](https://longbridge.com/en/news/263264213.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263264213.md)
---

# Foyou Pharma: 6 products are expected to be selected for the 11th batch of national centralized drug procurement

Foyou Pharma announced that six of its products are expected to be selected in the 11th national centralized drug procurement, including Fumaric Acid Lurasidone Tablets, Pravastatin Sodium Tablets, Cilostazol Tablets, Alendronate Sodium Tablets, Agomelatine Tablets, and Dopamine Hydrazine Tablets. If these products are selected and sales contracts are signed, it will help increase market share and have a positive impact on the company's future operating performance. At the same time, the products that the company did not win bids for, such as Dapagliflozin Tablets, did not generate sales in 2024, and the sales amount from January to September 2025 was 2.9413 million yuan, accounting for 0.1167% of the company's operating income during the same period, which will not have a significant impact on the company's production and operations

### Related Stocks

- [601089.CN](https://longbridge.com/en/quote/601089.CN.md)

## Related News & Research

- [Chemtrade Logistics Holds Guidance Amid Commodity Swings](https://longbridge.com/en/news/286831060.md)
- [PRECIOUS-Gold falls more than 2% as Treasury yields, dollar weigh amid inflation concerns](https://longbridge.com/en/news/286943432.md)
- [PRECIOUS-Treasury yields, dollar weigh on gold amid inflation concerns](https://longbridge.com/en/news/286929968.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)